<DOC>
	<DOCNO>NCT00845182</DOCNO>
	<brief_summary>Pioglitazone , drug use treatment type 2 diabetes show improve insulin sensitivity skeletal muscle , liver , fat cell . Despite beneficial effect pioglitazone improve insulin sensitivity reduce cardiovascular disease high risk type 2 diabetic patient , weight gain limit factor . Exenatide , another agent use treatment T2DM , improve glycemic control promote moderate weight loss . In proposal examine effect combination therapy pioglitazone plus exenatide body weight , fat topography , beta cell function , glycemic control , plasma lipid level subject type 2 diabetes mellitus compare treatment drug separately . Assessment beta cell function perform measure maximal insulin secretory capacity use maximal hyperglycemic stimulus combine intravenous arginine stimulus .</brief_summary>
	<brief_title>Effect Pioglitazone Exenatide Body Weight Beta Cell Function</brief_title>
	<detailed_description>The thiazolidinedione ( TZD ) class drug show improve insulin sensitivity skeletal muscle , liver , adipocytes anti-inflammatory cardioprotective effect . The beta cell function , measure insulin secretion/insulin resistance index OGTT , improve significantly . In present study , perform definitive assessment beta cell function TZD-treated diabetic patient measure maximal insulin secretory capacity use maximal hyperglycemic stimulus combine intravenous arginine stimulus . Despite beneficial effect pioglitazone improve insulin sensitivity reduce cardiovascular event high risk type 2 diabetic patient , weight gain limit factor primary care physician even though pioglitazone treatment lead redistribution fat muscle/liver/visceral area subcutaneous fat . Exenatide ( Byetta ) 39 amino acid peptide exhibit biological action similar GLP-1 . In clinical trial exenatide reduces HbA1c 1-1.2 % subject type 2 diabetes promotes moderate weight loss sustain 2 year . In proposal examine effect combination therapy pioglitazone plus exenatide body weight , fat topography , beta cell function , glycemic control , plasma lipid level subject type 2 diabetes mellitus compare monotherapy agent separately . We postulate combination therapy result significant weight loss ( contrast weight gain accompany pioglitazone treatment ) additive , even synergistic , effect improve beta cell function glycemic control type 2 diabetic patient inadequately control oral agent therapy metformin alone , sulfonylurea alone , combination metformin plus sulfonylurea . We also compare insulin secretion healthy control subject ( NGT , n=15 ) subject impair glucose tolerance ( IGT , n=15 ) evaluate relative decline beta cell function T2DM compare NGT IGT subject . NGT IGT subject participate OGTT Hyperglycemic clamp- receive medication .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . Diabetic patient must diet therapy alone diet plus sulfonylurea , diet plus metformin , diet plus sulfonylurea/metformin HbA1c ≥ 7.0 % . 2 . Patients must follow laboratory value : Hematocrit ≥ 34 vol % Serum creatinine ≤ 1.8 mg/dl AST ( SGOT ) ≤ 2 time upper limit normal ALT ( SGPT ) ≤ 2 time upper limit normal Alkaline phosphatase ≤ 2 time upper limit normal 3 . Patients must stable dose allow chronic medication 30 day prior enter study . 4 . Body weight must stable ( ± 34 pound ) three month prior study 5 . The normal healthy control group age , weight ( BMI ) , gender match diabetic group must normal OGTT accord ADA criterion . 6 . Subjects IFG/IGT FPG ( 100125mg/dl ) and/or 2h plasma glucose ( 140199mg/dl ) accord ADA criterion . 1 . Patients must type 1 diabetes . 2 . Patients must fast plasma glucose great 270 mg/dl HbA1c &gt; 10.0 % . 3 . Patients must receive thiazolidinedione insulin one week year prior randomization . 4 . Patients history clinically significant heart disease ( New York Heart Classification great class 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Type 2 diabetes pathogenesis , thiazolidinediones</keyword>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>Incretins</keyword>
	<keyword>Insulin secretion</keyword>
</DOC>